GlassScriptPhysician profile
William Tyler Flowers
NPI 1962855445
$7,768.23
in general payments reported to CMS, 2019-2025
37 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,272 · 2022: $1,760 · 2023: $1,369 · 2024: $2,146 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,716 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,716.37 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,419.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $905.15 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $791.14 | 2022-2025 | |
| Amgen INC. | $639.66 | 2021-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $557.23 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.79 | 2021-2024 | Jardiance |
| Lilly USA, LLC | $408.77 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $349.84 | 2023-2025 | Korlym |
| Pfizer INC. | $274.42 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $258.22 | 2021-2022 | |
| Evoke Pharma, INC. | $245.97 | 2022-2025 | Gimoti |
| Xeris Pharmaceuticals, INC. | $218.92 | 2022-2024 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $163.84 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Hikma Pharmaceuticals USA | $154.04 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $115.62 | 2023-2025 | Voquezna |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Flowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.